CDVA.CN stock surged 350.00% to C$0.045 during market hours on 02 Mar 2026, marking the session’s top gainer on the CNQ exchange in Canada. Trading volume reached 34,000.00 shares versus an average of 22,049.00, and the move comes ahead of CordovaCann Corp.’s earnings announcement scheduled 04 Mar 2026. The intraday range ran from a day low C$0.01 to a day high C$0.045, while the 50-day average sits at C$0.0286 and the 200-day average at C$0.04664, adding context to the rebound.

Price action and drivers for CDVA.CN stock

The main driver today was a sharp intraday ramp — CDVA.CN traded up C$0.03500 from yesterday’s close of C$0.01, a 350.00% one-day gain. Market participants flagged the upcoming earnings report on 04 Mar 2026 and thin free float as likely catalysts. The stock’s year high is C$0.23 and year low is C$0.005, which highlights the stock’s historical volatility.

Technical snapshot and trading indicators

Technicals show momentum but overbought readings: RSI at 65.40, CCI at 194.72, and ADX at 47.39 indicating a strong short-term trend. Price averages are mixed with a 50-day average of C$0.02860 and 200-day average of C$0.04664, so short-term strength sits against a longer-term neutral band. Relative volume of 1.54 suggests above-normal participation for a micro-cap name.

Fundamentals, valuation and Meyka AI grade

CordovaCann Corp. operates in Healthcare and Drug Manufacturers – Specialty & Generic on the CNQ in Canada with market cap C$4,941,156.00 and 109,803,460.00 shares outstanding. Key ratios include EPS -0.02, PE -2.25, price-to-sales 0.35, and current ratio 0.19, reflecting tight short-term liquidity. Meyka AI rates CDVA.CN with a score of 68.86 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI forecast and price target scenarios

Meyka AI’s forecast model projects a monthly target of C$0.09 and a quarterly target of C$0.04. Versus the current price C$0.045, the monthly projection implies an upside of 100.00%, while the quarterly projection implies a downside of 11.11%. Forecasts are model-based projections and not guarantees; treat them as scenario guidance for short-term traders.

Risks, liquidity and sector context

Major risks include very low liquidity, negative EPS, and a weak current ratio of 0.19, which heighten downside on a failed earnings print. CordovaCann sits in the Healthcare sector where average PE is 14.27, so CDVA.CN’s negative PE signals a different risk profile than larger peers. Small-cap microstructure can amplify moves, as today’s volume spike demonstrates.

Trading strategy and practical points for CDVA.CN trading

For traders, manage position size and set stop levels given the stock’s swing nature; suggested tactical price targets are conservative C$0.03, base C$0.07, and bull C$0.15 based on intraday liquidity and the stock’s year high C$0.23. Note the upcoming earnings on 04 Mar 2026 as a binary catalyst and confirm any corporate news before scaling into trades. See live data and updates on our platform Meyka stock page for CDVA.CN.

Final Thoughts

CDVA.CN stock’s 350.00% intraday surge to C$0.045 on 02 Mar 2026 made it the session’s top gainer on CNQ, driven by thin liquidity and an earnings event on 04 Mar 2026. Meyka AI’s forecast model projects a monthly target of C$0.09 (implied 100.00% upside versus the current price) and a quarterly target of C$0.04 (implied -11.11% downside). Our Meyka AI grade of 68.86/100 (B, HOLD) reflects mixed fundamentals: positive free cash flow metrics but weak liquidity and negative EPS. Short-term traders can exploit momentum, but risk management is essential given the stock’s micro-cap profile and sector differences versus larger healthcare peers. Forecasts and grades are model-based projections and not guarantees; investors should confirm results from CordovaCann’s upcoming earnings before making positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.